Bladder Cancer Clinical Trials in Houston, Texas

16 studies are recruiting for bladder cancer in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson, Houston, Texas
    Locations
    20 in total
    Run by
    IDEAYA Biosciences

    See if you can join NCT07277413 on ClinicalTrials.gov

  2. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    The University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    90 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT06172478 on ClinicalTrials.gov

  3. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

    The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with a…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    16 in total
    Run by
    EvolveImmune United, Inc

    See if you can join NCT07217171 on ClinicalTrials.gov

  4. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    39 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06465069 on ClinicalTrials.gov

  5. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

    The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    31 in total
    Run by
    Pfizer

    See if you can join NCT07090499 on ClinicalTrials.gov

  6. Measuring Surgical Recovery After Radical Cystectomy

    The intent of this study is to establish a registry of post-surgical outcomes in patients undergoing radical cystectomy at MD Anderson Cancer Center and the collaborating institutions. The goals of this initiative are to obtain a detailed baseline of multiple patient-reported outcomes (PRO) and cli…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    10 in total
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT03193970 on ClinicalTrials.gov

  7. A Study of MGC026 in Participants With Advanced Solid Tumors

    The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort ex…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    12 in total
    Run by
    MacroGenics

    See if you can join NCT06242470 on ClinicalTrials.gov

  8. IDOV-Immune for Advanced Solid Tumors

    This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potent…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    5 in total
    Run by
    ViroMissile, Inc.

    See if you can join NCT06910657 on ClinicalTrials.gov

  9. Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery

    In this 2-arm, non-randomized, phase II trial, the investigators will evaluate the efficacy and safety of comprehensive multimodal prehabilitation (CMMP) alone or in combination with planned neoadjuvant (NAT) in pre-frail/frail patients with probable/proven pancreaticobiliary, ovarian, kidney, or b…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Houston Methodist Neal Cancer Center, Houston, Texas
    Run by
    The Methodist Hospital Research Institute

    See if you can join NCT07050771 on ClinicalTrials.gov

  10. The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

    The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpos…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Md Anderson Cancer Center, Houston, Texas
    Locations
    18 in total
    Run by
    UMC Utrecht

    See if you can join NCT04075305 on ClinicalTrials.gov

  11. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    21 in total
    Run by
    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

  12. Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

    This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cell…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Baylor St. Luke's Medical Center, Houston, Texas
    Run by
    Baylor College of Medicine

    See if you can join NCT03740256 on ClinicalTrials.gov

  13. A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

    A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibit…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    16 in total
    Run by
    OncoNano Medicine, Inc.

    See if you can join NCT06022029 on ClinicalTrials.gov

  14. Blue Light Cystoscopy With Cysview® Registry

    Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Michael E. DeBakey VA Medical Center, Houston, Texas
    Locations
    23 in total
    Run by
    Photocure

    See if you can join NCT02660645 on ClinicalTrials.gov

  15. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Houston, Texas
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  16. A Beta-only IL-2 ImmunoTherapY Study

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    27 in total
    Run by
    Medicenna Therapeutics, Inc.

    See if you can join NCT05086692 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.